SecBot SecBot
8-K ·Filed May 5, 2026

RIGL

RIGEL PHARMACEUTICALS INC
BEARISH
Impact 7/10
Horizonimmediate Processed6mo ago SEC0001034842-26-000033
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The 40% EPS miss signals deteriorating profitability despite revenue growth. Watch for analyst downgrades and potential cost-cutting measures. The reaffirmed guidance provides a floor, but the collaboration termination adds pipeline uncertainty. Monitor next quarter's margins and any updates on the R289 Phase 1b study.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$26.67
T+0 close · May 5, 2026 · via day close
Latest settled
+38.02%
T+60 · $36.81
Vs SPY
+35.96%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $26.67entry
  2. T+1 · 6mo ago 0.00%α +0.33% · $26.67
  3. T+5 · 6mo ago +10.12%α +8.99% · $29.37
  4. T+20 · 6mo ago +13.61%α +10.83% · $30.30
  5. T+60 · 4mo ago +38.02%α +35.96% · $36.81
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rigel Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.44, missing consensus of $0.74 by 40.5%, despite 10% YoY revenue growth to $58.8M. Net income declined 24% YoY to $8.7M, and the company maintained its full-year revenue guidance of $275-290M. The miss was driven by higher R&D and SG&A costs, overshadowing strong product sales growth.

Key Financial Metrics

EPS
$0.44
est $0.74 · -40.5%
Revenue
$58.8M
+10.3% YoY
Rating
strong miss
Guidance
$275M to $290M
maintained

Key Facts

  • Q1 2026 total revenues: $58.8M (up 10% YoY from $53.3M)
  • Net product sales: $54.9M (up 26% YoY)
  • GAAP diluted EPS: $0.44 vs consensus $0.74 (40.5% miss)
  • Net income: $8.7M vs $11.4M in Q1 2025 (down 24%)
  • 2026 revenue guidance reaffirmed at $275-290M
  • Eli Lilly terminated collaboration on ocadusertib (effective June 15, 2026)
  • Debt restructured: repaid $40M term loan, drew $8M on new $40M revolver
  • Cash, cash equivalents and short-term investments: $146.7M as of March 31, 2026

Financial Impact

EPS miss of $0.30 vs consensus; net income decline of $2.8M YoY

epsnet incomeoperating expenses

Risk Factors

  • Eli Lilly collaboration termination may impact future royalty streams
  • Rising R&D and SG&A expenses pressuring margins
  • High dependence on TAVALISSE sales (68% of product revenue)
  • Potential need for additional capital if profitability continues to decline

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001034842-26-000033
Document: 0001034842-26-000033-index.html0001034842-26-000033
Document: 0001034842-26-000033.txt0001034842-26-000033
8-K Data (Synthetic)0001034842-26-000033

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026